These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20940192)

  • 1. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
    Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
    J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
    Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
    Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
    Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Zou HZ; Zhao YQ
    Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.